IMNM

+ Watchlist + Portfolio

Immunome, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $29.83
52-Week Range: $8.67 – $30.06
Market Cap: $3.19B
P/E (TTM): —
EPS (TTM): -2.38
Dividend Yield: —

Advanced Metrics

Price/Book: 6.06
PEG Ratio: —
Return on Equity: -64.03%
Return on Assets: -37.79%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 15.08
Debt/Equity: 0.01
Total Debt: $4.74M
Free Cash Flow: $-143.66M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $2.67B

IMNM Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$14.02M	$9.04M	$6.94M
Research & Development	$23.27M	$23.09M	$129.54M	$187.29M
Selling, General & Admin	$13.63M	$19.66M	$32.95M	$43.77M
Operating Expenses	$36.90M	$42.75M	$162.50M	$231.05M
Operating Income	-$36.90M	-$28.73M	-$153.46M	-$224.11M
EBITDA	-$36.27M	-$28.00M	-$151.35M	-$221.16M
Pretax Income	-$36.90M	-$106.81M	-$292.96M	-$212.39M
Net Income	-$36.90M	-$106.81M	-$292.96M	-$212.39M
Diluted EPS	-3.09	-5.38	-5.00	-2.43
Diluted Shares	12.13M	19.84M	58.64M	87.35M

IMNM Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$20.32M	$98.68M	$143.35M	$653.48M
Receivables	$847.00K	$289.00K	—	—
Current Assets	$22.65M	$144.70M	$221.34M	$660.78M
Total Assets	$24.05M	$148.54M	$240.24M	$683.19M
Current Liabilities	$7.33M	$21.83M	$54.31M	$44.99M
Total Debt	$291.00K	$1.65M	$4.83M	$3.85M
Total Liabilities	$7.39M	$28.66M	$59.08M	$48.84M
Retained Earnings	-$116.00M	-$222.81M	-$515.77M	-$728.16M
Shareholders' Equity	$16.65M	$119.88M	$181.16M	$634.34M
Working Capital	$15.32M	$122.87M	$167.03M	$615.79M

IMNM Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$28.69M	-$7.57M	-$110.79M	-$190.92M
Capital Expenditure	-$248.00K	-$831.00K	-$53.51M	-$15.93M
Free Cash Flow	-$28.94M	-$8.40M	-$164.30M	-$206.85M
Depreciation & Amortisation	$631.00K	$728.00K	$2.10M	$2.96M
Stock-Based Compensation	$5.33M	$6.22M	$15.75M	$25.69M
Investing Cash Flow	-$248.00K	-$30.48M	-$85.06M	$60.80M
Financing Cash Flow	$32.00K	$116.41M	$240.53M	$640.36M
Net Change in Cash	-$28.91M	$78.36M	$44.67M	$510.24M

IMNM Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$2.93M	$4.01M	$0.00	$0.00	$0.00
Research & Development	$36.87M	$40.45M	$49.19M	$60.77M	$46.38M
Selling, General & Admin	$10.69M	$10.04M	$10.95M	$12.09M	$12.95M
Operating Expenses	$47.56M	$50.49M	$60.14M	$72.86M	$59.33M
Operating Income	-$44.64M	-$46.48M	-$60.14M	-$72.86M	-$59.33M
EBITDA	-$43.91M	-$45.76M	-$59.41M	-$72.08M	-$58.58M
Pretax Income	-$41.64M	-$43.40M	-$57.46M	-$69.90M	-$53.84M
Net Income	-$41.64M	-$43.40M	-$57.46M	-$69.90M	-$53.84M
Diluted EPS	-0.52	-0.50	-0.65	—	-0.48
Diluted Shares	79.41M	87.01M	87.96M	—	113.14M

IMNM Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$257.61M	$143.88M	$272.64M	$653.48M	$582.69M
Current Assets	$323.13M	$277.43M	$279.92M	$660.78M	$594.31M
Total Assets	$342.69M	$296.29M	$299.38M	$683.19M	$619.79M
Current Liabilities	$30.80M	$22.88M	$31.45M	$44.99M	$27.41M
Total Debt	$4.77M	$4.14M	$4.01M	$3.85M	$3.69M
Total Liabilities	$35.57M	$27.02M	$35.46M	$48.84M	$31.11M
Retained Earnings	-$557.41M	-$600.81M	-$658.26M	-$728.16M	-$782.00M
Shareholders' Equity	$307.13M	$269.27M	$263.92M	$634.34M	$588.69M
Working Capital	$292.33M	$254.55M	$248.48M	$615.79M	$566.90M

IMNM Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$53.05M	-$49.40M	-$40.51M	-$47.95M	-$58.64M
Capital Expenditure	-$9.91M	-$905.00K	-$1.12M	-$4.00M	-$12.02M
Free Cash Flow	-$62.97M	-$50.31M	-$41.63M	-$51.95M	-$70.65M
Depreciation & Amortisation	$726.00K	$720.00K	$733.00K	$776.00K	$753.00K
Stock-Based Compensation	$5.70M	$5.35M	$6.75M	$7.89M	$7.95M
Investing Cash Flow	$5.09M	-$64.17M	$123.88M	-$4.00M	-$12.02M
Financing Cash Flow	$162.23M	-$55.00K	$45.39M	$432.80M	-$135.00K
Net Change in Cash	$114.26M	-$113.63M	$128.76M	$380.84M	-$70.79M

Market Snapshot

About

Immunome, Inc. is a biotechnology company developing targeted cancer therapies using its proprietary antibody discovery platform. The company's technology enables the identification of novel antibody targets from patients who have naturally mounted an immune response to their cancer. Immunome's pipeline includes multiple antibody-drug conjugates and bispecific antibodies in various stages of development. The company focuses on solid tumors where conventional therapies have shown limited efficacy. Immunome's patient-driven discovery approach offers a differentiated strategy in oncology drug development.